|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Chest pain, severe |
|
difficulty in swallowing |
|
heaviness, tightness, or pressure in chest and/or neck |
|
Anaphylactic or anaphylactoid reaction |
|
dermatitis, allergic |
|
seizures |
|
Injection site reaction |
|
irritation in the nose |
|
nausea or vomiting |
|
taste perversion |
|
Atypical sensations |
|
discomfort in jaw, mouth, throat, tongue, nasal cavity, or sinuses |
|
dizziness |
|
drowsiness |
|
flushing |
|
lightheadedness |
|
muscle aches, cramps, or stiffness |
|
weakness |
|
Anxiety |
|
general feeling of illness or tiredness |
|
vision changes |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiac arrhythmias |
|
>> Tachycardia |
|
>> Cerebrovascular accident |
|
>> Coronary artery disease, predisposition to |
|
>> Hepatic function impairment |
|
Renal function impairment |
|
Hypertension, controlled |
|
|
ADULT DOSE:
|
|
Antimigraine agent-
Oral, 25 to 100 mg (base) as a single dose. If necessary, additional doses up to 100 mg may be taken at intervals of at least two hours, up to a maximum of 300 mg a day .
For relief of migraine headache that returns after an initial treatment with sumatriptan injection, additional single oral doses of up to 50 mg may be given at intervals of at least two hours, up to a maximum of 200 mg a day.
The maximum single dose for patients with hepatic impairment should not exceed 50 mg.
Note: There is no evidence that an initial dose of 100 mg provides substantially greater relief than a dose of 25 mg. |
|
MAXIMUM ADULT DOSE:
|
|
Antimigraine agent-
Oral, not more than 300-mg (base) in twenty-four hours . |
|
PEDIATRIC DOSE:
|
|
Safety and efficacy in patients up to 18 years of age have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|